BIO-REFERENCE 2ND QTR HAS INCREASE OF 16% FOR FISCAL 2009.

Laboratories, Inc. (NASDAQ: BRLI), Elmwood Park,N.J., has released its second quarter, fiscal year 2009 earnings for the three months ending April 30. The company recorded current quarter revenues of $87,183, the best ever quarter in corporate history and an increase of 16% over the $75,180 recorded in the second quarter, fiscal year 2008. Operating income for Q2FY09 was $8,358, an increase of 34% over the Q2FY08 operating income of $6,215. Net income after taxes in Q2FY09 came in at $4,630 resulting in earnings per share (EPS) of $.33, up from the prior fiscal year second quarter net income after taxes of $3,427 and EPS of $.25. Gross profits on revenues for the current quarter were $42,297 resulting in a margin for gross profit on revenues of about 49%, a 17% improvement over the $36,182 reported for the prior fiscal year second quarter which resulted in a 48% margin. Revenue per patient for the second quarter of the current fiscal year was $76.74, an increase of 8% over the $70.95 reported for the same quarter of the prior fiscal year. The number of patients served increased more than 7% to 1,127 in the current quarter from the prior year second quarter total of 1,050. Esoteric business for the company was 52% of revenues for the second quarter of the current fiscal year compared to 47% in the same quarter of the prior fiscal year. Cash flow from operations for the quarter was just under $3.4 million positive. The company further noted that Days Sales Outstanding (DSO) of 104 days compared to Q1FY09 of 115 days and the prior fiscal year same quarter when the DSO were 109 days.

Six-month revenues increased to $162,918 (all six month numbers exclusive of a one-time restitution amount recorded in the first quarter of the current year), an increase of 15% over the same period revenues of $142,059 in the prior fiscal year. Operating income for the first six months of FY09 was $13,328, an increase of 27% over the prior fiscal year six month Operating income of $10,479. Net income after taxes for the first six months of the current year was $7,299 resulting in an EPS of $.53, an increase of 29% from the prior year same period net income after taxes of $5,635 which resulted in an EPS of $.41. The company reported gross profit on revenues for the current six month period of $77,992, resulting in a margin for gross profit on revenues of about 48%, the same as the prior year same period of $67,833 which also resulted in a margin of 48%. The number of patients served increased 4% to 2,092 in the first half of the current year from the prior year same period total of 2,013, despite having shown minimal improvement in the first quarter of the current year.

Marc D. Grodman, MD, CEO, commented "By all standards, our financial metrics have shown significant improvement and our achievements have been exceptional. We have posted better net revenues and better gross profits than we have ever reported in the company's history. Our second quarter numbers are far better than any we have ever posted in any second quarter of any fiscal year. We have seen the return of our historical trend of patient count growth as the economy, at least as it pertains to physician office visits, seems to have stabilized in our marketplace."

Dr. Grodman continued: "BioReference has truly asserted itself in the clinical laboratory world where we use better science and better service to fuel all of our growth initiatives. Within the markets in which we compete, we have assumed a leadership role demonstrated by our continued strong growth in specialized testing markets. GenPath, Women's Health, GeneDx and Correctional Health have all made significant contributions to our growth. Better Science and better service will lead the way. Our Women's Health program featuring "GenPap" and the genetic cardiology testing programs at GeneDx, are each based on innovative, disruptive technologies. GenPath continues to take market share and will lead the way in disruptive technologies that will provide answers that physicians both need and want. These initiatives did not occur overnight but as the result of planning, testing, development and investment over the past few years. We are guided by a sense of clinical relevance and a passion for the potential of laboratory science. Ultimately, these initiatives also will be deemed successful not only if they provide growth and opportunity but if they also improve patient care. That is the standard of success that we have and will always embrace. These programs are emblematic of both these efforts and our underlying principles, and that is how BioReference will continue to differentiate itself in the clinical marketplace, now and for years to come."

Dr. Grodman finally noted: "We reaffirm our guidance that we will see at least a 15% increase in our top-line revenues and a 20% increase in our net income. We have proven time and time again in the past that we know how to grow our company and we will continue to do so in the future as we continuously work to extract better profit to the bottom line."

About BioReference Laboratories, Inc.

BRLI is the third largest full service laboratory in the United States and the largest independent regional laboratory in the Northeastern market, primarily a clinical testing lab servicing physician offices with concentrations in the focused markets of esoteric testing, molecular diagnostics, anatomical pathology and correctional health care. BRLI operates as a national oncology laboratory under its GenPath label. Better science, superior technology and better service have enabled GenPath to earn a reputation as one of the premier hematopathology laboratories in the country. BRLI's innovative technology platform for sexually transmitted infections has enabled it to expand as a national laboratory in the area of Women's Health. GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and is typically recognized as the leading laboratory for testing of rare genetic diseases; GeneDx has now become a technology leader with GenomeDx, based on a CGH array platform and its NextGen sequence offerings that are currently offered in cardiology and will be offered in the future in other disease specific areas.

For more information, visit http://www.bioreference.com or call 201/791-2600.

Alpha-1 Foundation Announces the Million Dollar Match Program Made Possible by a Talecris Biotherapeutics Grant

Alpha-1 Foundation Announces the Million Dollar Match Program Made Possible by a Talecris Biotherapeutics Grant Talecris Will Double Research Donations up to $1 Million

Print Get the Mag Weekly Updates